Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Authors
Keywords
Metformin, Glycaemic Control, Liraglutide, Insulin Glargine, Exenatide
Journal
DRUGS
Volume 74, Issue 18, Pages 2161-2174
Publisher
Springer Nature
Online
2014-11-03
DOI
10.1007/s40265-014-0321-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AACE Comprehensive Diabetes Management Algorithm 2013
- (2015) Alan Garber et al. Endocrine Practice
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
- (2014) C. Mathieu et al. DIABETES OBESITY & METABOLISM
- Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes
- (2014) W. C. Lee et al. DIABETES OBESITY & METABOLISM
- Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) David J. Klein et al. Diabetes Technology & Therapeutics
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
- (2014) Patrick M. Zueger et al. PHARMACOECONOMICS
- Efficacy of Liraglutide in a Real-Life Cohort
- (2014) Anthony Heymann et al. Diabetes Therapy
- Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
- (2013) Stuart A. Ross et al. CURRENT MEDICAL RESEARCH AND OPINION
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- Do GLP-1-Based Therapies Increase Cancer Risk?
- (2013) M. A. Nauck et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
- (2013) A. Flint et al. DIABETES OBESITY & METABOLISM
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
- (2013) K. Hermansen et al. DIABETES OBESITY & METABOLISM
- One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
- (2013) Julio Rosenstock et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Comparative Effectiveness of Liraglutide Versus Sitagliptin in Type 2 Diabetes in the United Kingdom: A Retrospective Study in Primary Care
- (2013) M.E. Nyeland et al. VALUE IN HEALTH
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
- (2012) J. H. DeVries et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk
- (2012) K. G. Brodovicz et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
- (2012) Michael Horowitz et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Type 2 diabetes mellitus and the risk of acute pancreatitis
- (2012) Lin Yang et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2012) Yurong Zhang et al. PLoS One
- Diagnosis and Classification of Diabetes Mellitus
- (2011) DIABETES CARE
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
- (2011) A. H. Barnett DIABETES OBESITY & METABOLISM
- Liraglutide
- (2011) Caroline M. Perry DRUGS
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
- (2011) John B. Buse et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
- (2011) Kohei Kaku et al. Journal of Diabetes Investigation
- Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial
- (2011) Yutaka Seino et al. Journal of Diabetes Investigation
- Glycemic Control and Complications in Type 2 Diabetes Mellitus
- (2010) Mark Stolar AMERICAN JOURNAL OF MEDICINE
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care
- (2010) Mark Stolar AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
- (2009) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Liraglutide
- (2009) Katherine F. Croom et al. DRUGS
- Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
- (2009) Dhruba J. Chatterjee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started